TJ Biopharma
天境生物藥業（杭州）股份有限公司
Clinical-stage assets
| Asset | Stage at source date | Indication | Source date |
|---|---|---|---|
| Felzartamab; Greater China rights | Global Phase 3 in immune-mediated diseases; China myeloma BLA under review | Not disclosed | 2026-04-20 |
Licensing announcements since 2025
| Date | Counterparty | Asset / platform | Upfront | Near-term | Potential total | Stage at announcement |
|---|---|---|---|---|---|---|
| 2026-04-20 | Biogen Inc. | Felzartamab; Greater China rights | USD 100,000,000 | Not disclosed | ≤ USD 850,000,000 | Global Phase 3 in immune-mediated diseases; China myeloma BLA under review |